Wugen
wugen.comLocations
St. Louis, MO, USA
industry
Biotechnology · DeepTech · Health
Size
51-200 employees
Stage
Series B
founded in
2018
Wugen is a clinical-stage biotechnology company developing allogeneic, off-the-shelf cellular therapies for cancer, specifically targeting solid tumors, acute myeloid leukemia (AML), and T-cell malignancies. Their innovative NK cell and CAR-T immuno-oncology therapies are derived from healthy donors and are engineered to enhance their efficacy in eliminating cancer cells. With a strong pipeline supported by issued and pending patents, Wugen is positioned to address significant unmet needs in cancer treatment, aiming to provide convenient, effective therapies for patients.
Something looks off?Open jobs at Wugen
On-site & Remote
Seniority
Salary